FNN interview with Nox Chief Medical Officer on Interim Data
Filed with ASX · · 2 pages · English
Story so far
Earlier from Noxopharm
- Veyonda and Radiotherapy Delivers Clinical Benefits
- Principal Investigator Discusses LuPIN-1 Study
- NOX Receives $3.26M Federal Govt R&D Rebate
- DARRT-1 study advancing on basis of positive clinical data
- NOX announces Positive Data from CEP-1 Study of Veyonda
Later from Noxopharm
- Noxopharm to expedite Veyonda Clinical Program
- KZA: Kazia sells stake in Noxopharm
- Veyonda Chemotherapy Enhancement Program to be Expanded
- Idronoxil Confirmed as New Immuno-Oncology Drug
- Veyonda and Immuno-Oncology Effect Explained
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm